DA-9701

Phase 3Small molecule

SSeoul National University Hospital

DA-9701 is one of 2 small molecule programs targeting Functional Dyspepsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Functional DyspepsiaRecruiting

Functional DyspepsiaPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Functional Dyspepsia

#DrugCompanyPhaseTrials

Nereus

VVanda Pharmaceuticals

Phase 2

1 2

DA-9701

SSeoul National University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Functional Dyspepsia

NCT07686679

Clinical

Trials by Indication[1]

Gastrointestinal1 trial

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Completed·SSeoul National University Hospital·Phase 4·NCT02775591·147 enrolled

Parkinson's Disease1 trial

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Completed·SSeoul National University Hospital·Phase 4·NCT03022201·40 enrolled

Functional Dyspepsia1 trial

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia

Recruiting·DDong-A ST Co., Ltd.·Approved·NCT07686679·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DA-9701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-9701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-9701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSeoul National University Hospital

DA-9701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gastrointestinal1 trial

Parkinson's Disease1 trial

Functional Dyspepsia1 trial

References

Drug Info

Quick Facts

Related News